Ecomic Co., Ltd (TYO:3802)

Intra-Cellular Therapies Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	72	183	220	187	137
Depreciation & Amortization	120	121	117	86	56
Other Operating Activities	-30	-24	-86	-22	-75
Change in Accounts Receivable	7	-5	-39	-6	19
Change in Inventory	2	6	2	-	-
Change in Accounts Payable	-8	-105	37	38	-36
Change in Other Net Operating Assets	-14	29	13	-6	-4
Operating Cash Flow	149	205	264	277	97
Operating Cash Flow Growth	-27.32%	-22.35%	-4.69%	185.57%	-53.36%
Capital Expenditures	-47	-26	-24	-56	-38
Cash Acquisitions	-	-	109	-	-
Sale (Purchase) of Intangibles	-77	-39	-61	-97	-131
Investment in Securities	13	-	-3	-	-
Other Investing Activities	-5	-10	7	10	-29
Investing Cash Flow	-116	-75	28	-143	-198
Long-Term Debt Repaid	-114	-51	-49	-	-
Net Debt Issued (Repaid)	-114	-51	-49	-	-
Issuance of Common Stock	-	382	-	1	205
Dividends Paid	-56	-30	-22	-22	-16
Other Financing Activities	-	-2	-1	-	-13
Financing Cash Flow	-170	299	-72	-21	176
Foreign Exchange Rate Adjustments	-2	12	3	22	10
Miscellaneous Cash Flow Adjustments	-1	1	1	-1	1
Net Cash Flow	-140	442	224	134	86
Free Cash Flow	102	179	240	221	59
Free Cash Flow Growth	-43.02%	-25.42%	8.60%	274.58%	-70.05%
Free Cash Flow Margin	4.81%	8.30%	10.83%	12.59%	3.74%
Free Cash Flow Per Share	21.73	46.27	63.01	58.32	15.80
Cash Income Tax Paid	32	26	88	21	76
Levered Free Cash Flow	14.75	61.5	125.88	138.63	-120
Unlevered Free Cash Flow	15.38	62.13	126.5	138.63	-120
Change in Net Working Capital	10	102	33	-90	102

Source: S&P Global Market Intelligence. Standard template. Financial Sources.